Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05345002 · ClinicalTrials.gov registry record · Phase 2
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
A Phase 2 study of Glioma and Astrocytoma, sponsored by Stephen Bagley, MD, MSCE.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT05345002 is a Phase 2 study of Glioma and Astrocytoma that is actively recruiting participants, run by Stephen Bagley, MD, MSCE. The registered enrollment target is 55 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05345002, a Phase 2 study of Glioma and Astrocytoma, is actively recruiting participants, sponsored by Stephen Bagley, MD, MSCE.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. The Sponsor-Investigator hypothesizes that the proposed regimen will be safe and stimulate a robust anti-tumor immune response.
Conditions Studied
Interventions
- DRUG Retifanlimab
- DRUG All-trans retinoic acid
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-11-16 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05345002
The ClinicalTrials.gov registry entry for NCT05345002 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (74% lower). The listed sponsor is Stephen Bagley, MD, MSCE, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Glioma appearing as the primary indexed condition, and to 2 interventions - of which Retifanlimab is the first listed.
NCT05345002 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05345002 about?
NCT05345002 is a clinical study titled "All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma". This is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. The Sponsor-Investigator hypothesizes that the proposed regimen will be safe and stimulate a robust anti-tumor immune response.
What is the current status of trial NCT05345002?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2022-11-16. Estimated completion is 2028-06-01.
What conditions does trial NCT05345002 study?
This clinical trial studies the following conditions: Glioma, Astrocytoma, Oligodendroglioma, IDH Mutation.
What interventions are being tested in trial NCT05345002?
The interventions under investigation include: Retifanlimab (DRUG), All-trans retinoic acid (DRUG).
Who is sponsoring clinical trial NCT05345002?
This trial is sponsored by Stephen Bagley, MD, MSCE, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05345002 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
RECRUITING · Phase 2
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Methimazole in Patients With Progressive Glioblastoma
RECRUITING · Phase 2
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
A Study Utilizing Escitalopram in Glioma Patients
RECRUITING · Phase 2
-
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.